Send a Tweet
Most Popular Choices
Share on Facebook Share on Twitter Printer Friendly Page More Sharing
Best Web OpEds    H3'ed 12/30/15

Karma strikes again: Pharma company with ties to Martin Shkreli files for bankruptcy

Quicklink Submitted By     (# of views)   No comments
Follow Me on Twitter     Message Sheila Samples
Become a Fan
  (49 fans)
Copyrighted Image -
Copyrighted Image? DMCA
Martin Shkreli, the price-gouging pharmaceuticals CEO everyone loves to hate, may be the opposite of King Midas: Everything he touches shrivels and dies. A drugmaker that Shkreli recently took over has now filed for bankruptcy. Shkreli was elected chairman of the board and chief executive officer of KaloBios Pharmaceuticals, which produces benzidazole, in mid-November. Three weeks later, he bought a majority share in the company, allowing him to apply for exclusive selling rights to the drug. KaloBios is not the only company in turmoil thanks to having Shkreli at its helm. Turing Pharmaceuticals named Ron Tilles, the chairman of its board of directors, as the interim CEO after Shkreli resigned from the position on December 19, two days after his arrest. KaleBios had fired Shkreli after the charges were filed.
Read the rest of the story HERE:

At www.rt.com

 

Must Read 1   Valuable 1  
Rate It | View Ratings

Sheila Samples Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Sheila Samples is an Oklahoma writer and a former civilian US Army Public Information Officer. She is a Managing Editor for OpEd News, and a regular contributor for a variety of Internet sites.

Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Follow Me on Twitter     Writers Guidelines
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEdNews Newsletter
Name
Email
   (Opens new browser window)